Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial
Round 1
Reviewer 1 Report
Did you use MRI for simulation of liver lesions?
How did you categorized metastatic disease? Could you clarify?
How did you differentiate synchronous and metachronous disease?
Can you add a table with dose and fractionation utilized and relative percentages of patients?
Author Response
Thanks for your precious comments.
We did our best to follow your recommendations, as follows.
Did you use MRI for simulation of liver lesions?
Yes, when deemed helpful for simulation purposes and in absence of contraindications. Now clarified in the matherial and methods
How did you categorized metastatic disease? Could you clarify?
We followed the ESTRO-EORTC classification. Now clarified in the manuscript and added in the references
How did you differentiate synchronous and metachronous disease?
Disease was considered synchronous if metastases were diagnosed within 6 months from primary cancer occurrence. Added in the matherial and methods section
Can you add a table with dose and fractionation utilized and relative percentages of patients?
Required informations have been added in table 4.
Reviewer 2 Report
This manuscript is about Phase II non randomized trial of the treatment of liver and lung metastases from breast cancer with stereotactic body radiotherapy. The Authors did a great job with illustrating and explaining in their manuscript about the methods, side effects and the constraints of the radiotherapy. Since the development in the technic in the field of radiotherapy and the safety of the procedures due to the development in the software and hardware of the radiotherapy. This lead to deliver a high precision therapy for secondary tumors whether in the liver or lung without causing a high grade side effects. There was no grade III side effects. I recommended this manuscript to be publish.
Author Response
Thank you very much for your observations